Once the Food and Drug Administration approved Addyi, a failed antidepressant repackaged as a libido pill for women, drug-maker Valeant Pharmaceuticals bought the company selling Addyi for $1 billion. If they were expecting to cash in on a blockbuster drug, early sales aren’t very promising: in the first month, only 227 prescriptions for the drug have been written. [More]
addyi
FDA Approves Addyi, Which Is Absolutely Not Viagra For Women
By 8.19.15
Late yesterday, the Food and Drug Administration approved the drug flibanserin, which will hit the market under the brand name Addyi. You’ll see a lot of headlines and smirking news anchors using the phrase “Viagra for women” when talking about the drug, but that’s only correct in one sense. This drug wouldn’t be for sale to patients at all if it weren’t for the success of Viagra as a drug marketed directly to consumers. [More]
FDA Closer To Approving Twice-Rejected Female Libido Drug
By 6.5.15
Yesterday, a Food and Drug Administration advisory panel recommended that the agency approve a new drug, flibanserin, which would be marketed under the brand name Addyi. In headlines and in news reports, you see references to the drug as a “pink Viagra” or “Viagra for women.” Yet the drug works on the brain, not the genitals, and critics say that its side effects may not be worth its proven benefits. The FDA has already rejected the drug twice. [More]
